Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224920 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8BCHELGALS3PDE4D | |
| SCHEMBL2536430 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8BCHELGALS3PDE4D | |
| SCHEMBL9791495 | 0.93 | SLC6A2 (0.62) | SLC6A2LGALS8BCHELGALS3PDE4D | |
| SCHEMBL9791489 | 0.93 | SLC6A2 (0.62) | SLC6A2LGALS8BCHELGALS3PDE4D | |
| SCHEMBL11513219 | 0.92 | SLC6A2 (0.52) | SLC6A2LGALS8BCHELGALS3 | |
| SCHEMBL181077 | 0.90 | SLC6A2 (0.47) | SLC6A2BCHE | |
| SCHEMBL181126 | 0.90 | SLC6A2 (0.47) | SLC6A2BCHE | |
| SCHEMBL181127 | 0.90 | SLC6A2 (0.47) | SLC6A2BCHE | |
| SCHEMBL6929599 | 0.90 | SLC6A2 (0.47) | SLC6A2BCHE | |
| SCHEMBL2172329 | 0.90 | SLC6A2 (0.47) | SLC6A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388264-A1 | COMPOUND RETAINED IN TUMOR | Toyo Suisan Kaisha, Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110254443-A1 | PHASE AND FREQUENCY LOCKED MAGNETRON | MUONS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | OHTA KEISUKE | 2010-08-12 | — | — | US | disclosed |
| US-4987223-A | INTERMEDIATES FOR GLYCOSIDE ENZYME SUBSTRATES | CHOAY S.A. (FR) | 1991-01-22 | — | — | US | disclosed |
| EP-0084999-A1 | Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications | D.R.O.P.I.C. (Société Civile) (FR) | 1983-08-03 | — | — | EP | disclosed |
| EP-0082793-A1 | Derivatives with a uronic acid structure, their preparation and their biological applications | D.R.O.P.I.C. (Société Civile) (FR) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | HRH3, HRH4, HNRNPH3 | SLC6A2 2975/4885LGALS8 3075/4885BCHE 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.